Global Secondary Hyperparathyroidism Drug Market Size By Type (Evocalcet, LNP-1892), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Secondary Hyperparathyroidism Drug Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 7.3 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2023–2031). This growth is driven by the increasing prevalence of chronic kidney disease (CKD), aging populations, and the expanding patient base undergoing dialysis—primary risk factors contributing to secondary hyperparathyroidism (SHPT). The market is also being bolstered by heightened awareness among healthcare professionals, improved diagnostic capabilities, and innovations in therapeutic formulations.

Drivers:

Rising Prevalence of Chronic Kidney Disease (CKD):

CKD remains the most significant risk factor for SHPT. With the global CKD burden increasing due to aging populations and rising incidences of diabetes and hypertension, demand for SHPT drugs has seen substantial growth.

Growing Dialysis Population:

An increasing number of patients undergoing long-term dialysis experience SHPT, driving the demand for phosphate binders, vitamin D analogs, and calcimimetics.

Therapeutic Innovations and Personalized Medicine:

Ongoing R&D has led to the development of novel drug classes and extended-release formulations, improving treatment adherence and patient outcomes. Companies are also integrating personalized treatment pathways for better efficacy.

Restraints:

Adverse Effects and Drug Tolerability Issues:

Some SHPT drugs, particularly calcimimetics, are associated with gastrointestinal side effects and poor patient tolerance, which can affect compliance and overall treatment outcomes.

High Treatment Costs and Reimbursement Barriers:

The high cost of SHPT medications and variable reimbursement policies across regions, especially in low- and middle-income countries, can limit patient access to effective therapies.

Opportunity:

Expansion in Emerging Healthcare Markets:

Countries in Asia-Pacific and Latin America are witnessing an upsurge in CKD prevalence along with improving healthcare infrastructure. These trends present lucrative growth avenues for SHPT drug manufacturers.

Development of Next-Gen Therapies:

The push toward non-calcium-based phosphate binders and new delivery mechanisms offers significant commercial potential. Biopharmaceutical companies investing in long-acting formulations and combination therapies are likely to capitalize on unmet needs.

Market by Drug Class Insights:

The Calcimimetics segment led the market in 2023, attributed to their effectiveness in lowering parathyroid hormone (PTH) levels without increasing calcium or phosphate concentrations. Meanwhile, Vitamin D analogs continue to hold a significant share due to their historical use and improved formulations that reduce hypercalcemia risks.

Phosphate binders are expected to see moderate growth, particularly non-calcium-based types, which are increasingly preferred due to lower cardiovascular risk profiles.

Market by End-use Insights:

Hospitals accounted for the largest share in 2023, driven by the administration of SHPT treatments in conjunction with dialysis and nephrology consultations. However, specialty clinics and ambulatory care centers are witnessing rising adoption due to growing outpatient management of SHPT.

Market by Regional Insights:

North America dominated the global market in 2023, supported by high awareness, advanced healthcare infrastructure, and a large dialysis population. Asia-Pacific is expected to be the fastest-growing region due to rapid urbanization, healthcare expenditure growth, and increasing CKD incidence in nations like China and India.

Competitive Scenario:

Key players in the Global Secondary Hyperparathyroidism Drug Market include Amgen Inc., Kyowa Kirin Co., Ltd., Teva Pharmaceuticals, AbbVie Inc., Dr. Reddy’s Laboratories, Sanofi S.A., Cipla Ltd., and OPKO Health, Inc. These companies are focused on product innovation, expansion into untapped markets, and strategic collaborations to strengthen their market share.

Scope of Work – Global Secondary Hyperparathyroidism Drug Market

Key Market Developments:

2023: Amgen expanded the global distribution of its leading SHPT drug, etelcalcetide, into Southeast Asian countries, addressing regional access issues.

2024: Kyowa Kirin launched a next-generation oral calcimimetic in Japan with improved bioavailability and reduced GI side effects.

2025: Dr. Reddy’s Laboratories announced regulatory approvals in Latin America for its vitamin D analog generic portfolio, expanding SHPT drug accessibility.

FAQs:

What is the current market size of the Global Secondary Hyperparathyroidism Drug Market?

The market size in 2023 was valued at USD 4.1 billion.

What is the major growth driver of the Global Secondary Hyperparathyroidism Drug Market?

The increasing prevalence of chronic kidney disease and growing dialysis population are key growth drivers.

Which is the largest region during the forecast period in the Global Secondary Hyperparathyroidism Drug Market?

North America is expected to remain the largest region due to advanced healthcare infrastructure and high disease prevalence.

Which segment accounted for the largest market share in the Global Secondary Hyperparathyroidism Drug Market?

The Calcimimetics segment held the largest market share in 2023.

Who are the key market players in the Global Secondary Hyperparathyroidism Drug Market?

Leading players include Amgen Inc., Kyowa Kirin Co., Ltd., Teva Pharmaceuticals, AbbVie Inc., and Dr. Reddy’s Laboratories.